Monoclonal antibodies for systemic lupus erythematosus (SLE)

Claudio Ponticelli, Gabriella Moroni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A number of monoclonal antibodies (mAb) are now under investigation in clinical trials to assess their potential role in Systemic Lupus Erythematosus (SLE). The most frequently used mAb is rituximab, which is directed against CD20, a membrane protein expressed on B lymphocytes. Uncontrolled trials reported an improvement of SLE activity in non-renal patients and other studies even reported an improvement of severe lupus nephritis unresponsive to conventional treatments. However two randomized trials failed to show the superiority of rituximab over conventional treatment in non renal SLE and in lupus nephritis. Preliminary trials reported promising results with epratuzumab, a humanized mAb directed against CD22, and with belimumab, a human mAb that specifically recognizes and inhibits the biological activity of BLyS a cytokine of the tumor- necrosis-factor (TNF) ligand superfamily. Other clinical trials with mAb directed against TNF-alpha, interleukin-10 (Il-10), Il-6, CD154, CD40 ligand, IL-18 or complement component C5 are under way. At present, however, in spite of good results reported by some studies, no firm conclusion on the risk-benefit profile of these mAbs in patients with SLE can be drawn from the available studies.

Original languageEnglish
Pages (from-to)300-322
Number of pages23
JournalPharmaceuticals
Volume3
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Systemic Lupus Erythematosus
Monoclonal Antibodies
Lupus Nephritis
Tumor Necrosis Factors
Complement C5
Clinical Trials
Antibodies, Monoclonal, Humanized
CD40 Ligand
Interleukin-18
Interleukin-10
Membrane Proteins
B-Lymphocytes
Tumor Necrosis Factor-alpha
Cytokines
Kidney
Therapeutics
Rituximab

Keywords

  • Lupus nephritis
  • Monoclonal antibodies
  • Rituximab
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Monoclonal antibodies for systemic lupus erythematosus (SLE). / Ponticelli, Claudio; Moroni, Gabriella.

In: Pharmaceuticals, Vol. 3, No. 1, 2010, p. 300-322.

Research output: Contribution to journalArticle

Ponticelli, Claudio ; Moroni, Gabriella. / Monoclonal antibodies for systemic lupus erythematosus (SLE). In: Pharmaceuticals. 2010 ; Vol. 3, No. 1. pp. 300-322.
@article{1e96c86c0fc541c69c0258b0987fe581,
title = "Monoclonal antibodies for systemic lupus erythematosus (SLE)",
abstract = "A number of monoclonal antibodies (mAb) are now under investigation in clinical trials to assess their potential role in Systemic Lupus Erythematosus (SLE). The most frequently used mAb is rituximab, which is directed against CD20, a membrane protein expressed on B lymphocytes. Uncontrolled trials reported an improvement of SLE activity in non-renal patients and other studies even reported an improvement of severe lupus nephritis unresponsive to conventional treatments. However two randomized trials failed to show the superiority of rituximab over conventional treatment in non renal SLE and in lupus nephritis. Preliminary trials reported promising results with epratuzumab, a humanized mAb directed against CD22, and with belimumab, a human mAb that specifically recognizes and inhibits the biological activity of BLyS a cytokine of the tumor- necrosis-factor (TNF) ligand superfamily. Other clinical trials with mAb directed against TNF-alpha, interleukin-10 (Il-10), Il-6, CD154, CD40 ligand, IL-18 or complement component C5 are under way. At present, however, in spite of good results reported by some studies, no firm conclusion on the risk-benefit profile of these mAbs in patients with SLE can be drawn from the available studies.",
keywords = "Lupus nephritis, Monoclonal antibodies, Rituximab, Systemic lupus erythematosus",
author = "Claudio Ponticelli and Gabriella Moroni",
year = "2010",
doi = "10.3390/ph3010300",
language = "English",
volume = "3",
pages = "300--322",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - Monoclonal antibodies for systemic lupus erythematosus (SLE)

AU - Ponticelli, Claudio

AU - Moroni, Gabriella

PY - 2010

Y1 - 2010

N2 - A number of monoclonal antibodies (mAb) are now under investigation in clinical trials to assess their potential role in Systemic Lupus Erythematosus (SLE). The most frequently used mAb is rituximab, which is directed against CD20, a membrane protein expressed on B lymphocytes. Uncontrolled trials reported an improvement of SLE activity in non-renal patients and other studies even reported an improvement of severe lupus nephritis unresponsive to conventional treatments. However two randomized trials failed to show the superiority of rituximab over conventional treatment in non renal SLE and in lupus nephritis. Preliminary trials reported promising results with epratuzumab, a humanized mAb directed against CD22, and with belimumab, a human mAb that specifically recognizes and inhibits the biological activity of BLyS a cytokine of the tumor- necrosis-factor (TNF) ligand superfamily. Other clinical trials with mAb directed against TNF-alpha, interleukin-10 (Il-10), Il-6, CD154, CD40 ligand, IL-18 or complement component C5 are under way. At present, however, in spite of good results reported by some studies, no firm conclusion on the risk-benefit profile of these mAbs in patients with SLE can be drawn from the available studies.

AB - A number of monoclonal antibodies (mAb) are now under investigation in clinical trials to assess their potential role in Systemic Lupus Erythematosus (SLE). The most frequently used mAb is rituximab, which is directed against CD20, a membrane protein expressed on B lymphocytes. Uncontrolled trials reported an improvement of SLE activity in non-renal patients and other studies even reported an improvement of severe lupus nephritis unresponsive to conventional treatments. However two randomized trials failed to show the superiority of rituximab over conventional treatment in non renal SLE and in lupus nephritis. Preliminary trials reported promising results with epratuzumab, a humanized mAb directed against CD22, and with belimumab, a human mAb that specifically recognizes and inhibits the biological activity of BLyS a cytokine of the tumor- necrosis-factor (TNF) ligand superfamily. Other clinical trials with mAb directed against TNF-alpha, interleukin-10 (Il-10), Il-6, CD154, CD40 ligand, IL-18 or complement component C5 are under way. At present, however, in spite of good results reported by some studies, no firm conclusion on the risk-benefit profile of these mAbs in patients with SLE can be drawn from the available studies.

KW - Lupus nephritis

KW - Monoclonal antibodies

KW - Rituximab

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=77951948731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951948731&partnerID=8YFLogxK

U2 - 10.3390/ph3010300

DO - 10.3390/ph3010300

M3 - Article

VL - 3

SP - 300

EP - 322

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 1

ER -